12-Month Stability of Diurnal IOP Control on Cosopt

Condition(s) targeted: Glaucoma

Intervention: Cosopt (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: West Virginia University

Official(s) and/or principal investigator(s):
Anthony D Realini, MD, Principal Investigator, Affiliation: West Virginia University

To determine the stability of diurnal intraocular pressure in eyes with glaucoma treated with Cosopt

Official title: 12-Month Stability of Diurnal IOP Control on Cosopt

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome:

Diurnal IOP control

Adverse events

Detailed description: Glaucoma is a potentially-blinding but treatable eye disease. A major risk factor for glaucoma is elevated intraocular pressure (IOP). IOP is a dynamic variable (like blood pressure)—it changes over time. The more it changes, the more likely patients are to get worse. Glaucoma is treated by lowering IOP. Cosopt is a medication that lowers IOP. Little is known about how well Cosopt reduces IOP fluctuations. In this study, we plan to measure the IOP in both eyes of 10 glaucoma patients treated with Cosopt, every 2 hours from 8am to 8pm, on five separate days over a one-year period. Untreated baseline IOP will be measured on a similar long day before beginning treatment with Cosopt. This methodology will allow us to compare IOP fluctuations with and without Cosopt, and also to learn about long-term control of IOP fluctuations in eyes treated with Cosopt.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- bilateral OAG

Exclusion Criteria:

- contraindications to Cosopt

- pathology affecting tonometry

Starting date: September 2006
Ending date: March 2008
Last updated: March 28, 2007